Enalare Therapeutics Snags BARDA Contract for Intramuscular ENA-001
Enalare Therapeutics has secured a contract from the Biomedical Advanced Research and Development Authority (BARDA) worth up to $50.3 million for its investigational respiratory stimulant ENA-001.
The contract from the HHS agency is focused on developing ENA-001 in an intramuscular formulation for treatment for patients experiencing drug overdose. It may also be used as a medical countermeasure for mass casualty events.
The award will fund pre-clinical toxicology, human clinical studies, drug and device manufacturing and regulatory submission for a formulation of ENA-001 suitable for community use, the company said.
Enalare said it intends to start additional clinical trials with ENA-001 for several indications “in the near term.”
Enalare Therapeutics
Enalare Therapeutics Inc. is a clinical stage biopharmaceutical company dedicated to developing and commercializing novel therapies for patients suffering from life threatening acute respiratory and critical care conditions, including respiratory depression caused by drug overdose, post-surgery, and other conditions.
September 29, 2022
